Far From Certican: Novartis Hopes REMS Will Tip Balance For Kidney Transplant Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's cardio-renal committee will weigh whether a communication-focused risk management plan can assuage concerns about renal toxicity and slow wound healing.